Nivolumab for Urothelial Cancer Appraisal Terminated

NICE Technology Appraisals

Published March 17th, 2026

Detected March 17th, 2026

Summary

NICE has terminated the appraisal of nivolumab for urothelial cancer because the company failed to submit evidence. The guidance will be reviewed if the company decides to make a submission in the future.

View original document View source feed page

What changed

NICE has terminated the technology appraisal guidance (TA1141) for nivolumab (Opdivo) in combination with chemotherapy for untreated unresectable or metastatic urothelial cancer. The appraisal was terminated because the company responsible for the submission did not provide the necessary evidence. NICE is unable to make a recommendation on the use of this treatment under these circumstances.

This termination means that NICE will not issue a recommendation for nivolumab for this indication at this time. Healthcare providers and pharmaceutical companies should note that the guidance will only be reconsidered if the company decides to resubmit the evidence. No immediate actions are required from regulated entities, but they should be aware that this specific appraisal process has concluded without a positive recommendation due to a lack of submission.

Source document (simplified)

Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)

Technology appraisal guidance
TA1141
Published:

17 March 2026

Download guidance (PDF)

Overview

NICE is unable to make a recommendation on nivolumab (Opdivo) for untreated unresectable or metastatic urothelial cancer. This is because the company did not provide an evidence submission.

Last reviewed: 17 March 2026

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.